Propanc Health, AmatsiQBiologicals Ink Mfg. Pact

Propanc Health Group, an emerging healthcare company focused on developing treatments for cancer, has entered a contract manufacturing agreement with AmatsiQBiologicals, based in Gent, Belgium, for the development and GMP production of certain enzymes for development purposes, including first-in-man studies for the company’s lead product, PRP.
 
PRP is a novel formulation of two proenzymes mixed in a synergistic ratio to target cancer stem cells in solid tumors. The GMP manufacture of PRP as an injectable drug product requires specialized activities in order to meet the highest quality and safety standards for future human use.
 
“This major contract represents a significant step forward for the development of PRP,” said James Nathanielsz, Propanc’s chief executive officer. “The process towards securing the services of AmatsiQBiologicals was extensive, taking a number of months to draft, plan and execute. I am very confident we have identified a highly capable partner who will assist us with delivering a quality finished product for human use.”
 
“We are very pleased that Propanc has chosen to partner with AmatsiQBiologicals for the development and manufacturing of Propanc’s lead product, PRP,” said Annie Van Broekhoven, AmatsiQBiologicals’ chief executive officer. “This project really fits very well with our capabilities and we are confident we can deliver on time the GMP grade PRP material required for Propanc’s clinical studies.”